Figure 6.

BCMA-CAR-T cells significantly block growth of subcutaneous large size established (500 mm³). RPMI8226 xenograft tumors. (A) NSG mice were injected subcutaneously with RPMI8226 myeloma cells and tumor size was measured bi-weekly with calipers. On days 27 and 31 (arrows), the mice received BCMA CAR-T cells or mock CAR-T cells intravenously; * p < 0.0001 for BCMA CAR-T cells versus mock CAR-T cells. (B) The tumors were excised and photographed. (C) The excised tumors were weighed; * p < 0.05 for BCMA CAR-T cells versus mock CAR-T cells. (D) The mice were weighed weekly during the study. (E) Sections of the tumors were stained immunohistochemically (brown color) with antibodies specific for human CD3ζ, Ki-67 and cleaved caspase-3. Top row: tumors from mice receiving mock CAR-T cells. Bottom: tumors from mice receiving BCMA CAR-T cells. Blue color: nucleus counterstain. Original magnification 400×.